|Traded as||Euronext: VLA|
|Fate||established through a merger of former Intercell and Vivalis SA|
|Thomas Lingelbach (CEO), Frédéric Grimaud (Chairman of the supervisory board)|
|Products||Development of vaccines|
Marketed vaccines generated by Valneva include Ixiaro, a vaccine against Japanese encephalitis (approved in Europe, America and Australia) and Dukoral, a vaccine against cholera (approved in Europe, America and Australia)
Some of its candidates have failed in clinical trials: VLA43, a therapeutic vaccine against Pseudomonas Aeruginosa, V710, a therapeutic vaccine against Staphylococcus aureus (in collaboration with Merck), and IC41, therapeutic vaccine against hepatitis C
- "Valneva SE company profile, wiener börse". Retrieved 2017-09-02.
- "Ixiaro, Japanese-encephalitis vaccine (inactivated, adsorbed)". European Medicines Agency (EMA). 2009-06-05. Retrieved 2017-04-25.
- "Dukoral, cholera vaccine (inactivated, oral)". European Medicines Agency (EMA). 2009-04-30. Retrieved 2017-04-25.
- "Valneva writes off hospital-acquired infection vaccine following PhII/III miss". FierceBiotech, Questex LLC. 2016-09-01. Retrieved 2017-04-25.
- "Merck ends trial of Intercell's MRSA vaccine". Reuters. 2011-06-08. Retrieved 2017-04-25.
- "Intercell Hepatitis C Vaccine Meets Primary Endpoints". FDA News. 2007-08-22. Retrieved 2008-08-15.
|This French corporation or company article is a stub. You can help Wikipedia by expanding it.|
|This article on an Austrian company is a stub. You can help Wikipedia by expanding it.|